U.S. markets open in 4 hours 30 minutes
  • S&P Futures

    -17.25 (-0.39%)
  • Dow Futures

    -76.00 (-0.22%)
  • Nasdaq Futures

    -90.00 (-0.59%)
  • Russell 2000 Futures

    -6.70 (-0.37%)
  • Crude Oil

    -1.21 (-1.35%)
  • Gold

    -22.30 (-1.13%)
  • Silver

    -0.41 (-1.72%)

    -0.0010 (-0.10%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.46 (+3.04%)

    -0.0043 (-0.35%)

    -0.0050 (-0.00%)
  • Bitcoin USD

    -264.00 (-0.97%)
  • CMC Crypto 200

    -4.92 (-0.85%)
  • FTSE 100

    -41.60 (-0.54%)
  • Nikkei 225

    -452.75 (-1.37%)

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

Kamada Ltd.
Kamada Ltd.

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2022, prior to the open of the U.S. financial markets on Tuesday, November 22, 2022.

Kamada management will host an investment community conference call on Tuesday, November 22, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel) or 1 201-689-8263 (International) and entering the conference identification number: 13734312. The call will also be webcast live on the Internet at:

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada
Kamada Ltd. (the “Company”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel through 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Chaime Orlev
Chief Financial Officer

Bob Yedid
LifeSci Advisors, LLC